Coherus BioSciences

Jefferies 2016 London Healthcare Conference November 16, 2016





Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this presentation, including statements regarding Coherus' plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus' expectations regarding its ability to advance its intellectual strategy for CHS-1420, its ability to advance its CHS-1701, CHS-0214, CHS-1420, CHS-5217 and CHS-3351 biosimilar drug candidates, complete bridging studies for CHS-0214 and CHS-1420, obtain BLA approval for CHS-1701, submit a BLA for CHS-1420 in the U.S., file an MAA for CHS-0214 in the E.U., file at least one IND on a second wave biosimilar pipeline candidate and enter into collaborations for CHS-1701 commercialization ex-U.S., for CHS-131 and for its immunology (Anti-TNF) pipeline. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Quarterly Report on Form 10-Q for the period ended September 30, 2016 and its future periodic reports to be filed with the Securities and Exchange Commission.








• Introduction and Company Summary

- Program Highlights
- The Commercial Opportunity



Coherus BioSciences is a Leading Biosimilars Company





Megatrends Drive >\$100 Billion Opportunity

Surge in 2012 – 2020 patent expirations

Healthcare reform / regulatory enablement

Better analytic tools enable comparability


Payer need for biologics cost control

>**\$100 Billion** In 2015 Originator Global Sales



Source: EvaluatePharma: 29 originator products with > \$1 B in global sales losing patent exclusivity in at least one major market through 2020 had ~\$106 B in 2015 global sales


Key Uncertainties Continue to Decline and Path to Market has Become More Clear




Zarxio® is a registered trademark of Novartis AG

(1) Trend lines illustrative in nature (2) Coherus believes IPR final decisions on AbbVie's RA dosing patent IPR's are likely; (3) On November 7, 2016, the USPTO denied institution of Coherus' IPR against AbbVie's '166 (formulation) patent; However, the Company's established IP strategies include advancement of alternative formulations and corresponding legal strategies intended to address the '166 patent.

2016 is a Transformational Year with Multiple Program Milestones and Catalysts



US regulatory pathway is established, and full-label extrapolation is achievable





- Critical quality attributes determine biological activity
- Deep understanding of the originator attributes is critical for regulatory success



Totality of the data drives fullindication labeling




Zarxio and Inflectra both approved with full label under 351(k) pathway



Amgen adalimumab (Amjevita) and Sandoz etanercept (Erelzi) also approved across all eligible indications



Differentiated Platform Navigates the Pathway to Approval







- Introduction and Company Summary
- Program Highlights
- The Commercial Opportunity



CHS-1701 Pegfilgrastim Biosimilar: Significant Near-term Commercial Opportunity



- Complex, well defined molecule with limited heterogeneity
- ✓ Achieved high-level of analytical similarity



Tuning


- ✓ Successful scale-up, stable formulation
- Secured commercial supply through long-term agreement with KBI



- Efficacy demonstrated in healthy volunteers
- Successful immunogenicity trial
- ✓ BLA accepted



✓ Key patents either expired or avoided



(1) With U.S. FDA registration focus



Source: EvaluatePharma, First Word

CHS-1701 Pegfilgrastim Biosimilar: Positive Pivotal PK/PD Study Results

20

15 10


0 24

CHS-1701-05 study

Positive topline results

122 healthy subjects

- Randomized, singleblind, three-sequence, three-period crossover study
- Study assessed PK, PD, and safety (incl. immunogenicity) of CHS-1701 compared to Neulasta



PK results - Mean (±SD) peofilorastim concentration Neulasta and CHS-1701 (ng/mL)

PD results – Mean (±SD) absolute neutrophil count Neulasta and CHS-1701 (10^9/L)

Scheduled Time (hour)

- Study met all co-primary endpoints:
 - PK: Cmax and Area Under the Curve (AUC)
 - PD: absolute neutrophil count (ANC) and AUC
- 90% CI for the GMR well contained within the pre-specified margins of 80% to 125%
- Similar safety profiles of CHS-1701 and Neulasta with no serious adverse events or study discontinuations for either arm



CHS-1701 Pegfilgrastim Biosimilar: High-quality Commercial Manufacturing in Place

Key Partnership Terms with KBI

Term	3 years with options to extend
COGS	~5% of sales price
Current capacity commitment	~\$1B in annual sales
Readiness status	Qualification lots completed Preparing for Inspection



Cornerstone of US oncology franchise



Unencumbered global rights to ~\$5B market opportunity



Loading supply chain to support mid 2017 launch



Low COGS secures long-term sustainability



CHS-131 Novel Oral Therapy in RRMS: Positive Phase 2b Efficacy Data


Phase 2b study design in RRMS patients

Inclusion criteria

- 227 patients with RRMS ≤ 3 years
- Treatment-naïve to DMT for MS
- EDSS of 0-6 at screening
- > 1 CE lesion on MRI within last year
- < 10 CE lesions at screening

Study design

- Parallel, double-blind, placebo-controlled
- 3 study arms, CHS-131 3mg, CHS-131 1mg and placebo
- Primary endpoint was reduction in cumulative number of total CE lesions determined by monthly MRI from baseline to week 24



Abbreviations: RRMS = Relapsing-Remitting Multiple Sclerosis, CE = Contrast-Enhancing, DMT = Disease Modifying Treatment, MRI = Magnetic Resonance Imaging



14 Copyright ©2016 All Rights Reserved.

CHS-131 Novel Oral Therapy in RRMS: Target product profile addresses important patient needs

RRMS market is large and fragmented		d fragmented	CHS-131 proposition – oral formulation with differentiated safety profile	
RRMS market by class, \$ B		В	Unique mechanism of action with potent	
19.5	23.1		anti-inflammatory effects without evidence of immunosuppression	
10.6	9.2	Approved - ABCRs	 Potential first-line therapy alone or in combination with other MS disease 	
10.0	3.1	Approved - orals	modifying therapies	
	4.5	Approved - other		
6.7 2.2	6.3	Pipeline	 Safety demonstrated with no serious adverse events in over 600 patients, and n signs of leukopenia 	
2015	2024		0.9.10 01 100.100	



CHS-0214 Etanercept Biosimilar: Addresses Large Commercial Opportunity



A very complex biological on the market
High similarity match with originator




Successful pre-commercial scale-up
 Stable proprietary formulation



- ✓ Positive top-line Ph 3 results in RA
- Positive top-line Ph 3 results in psoriasis



Key EU patents either expired or avoided
 Issued patent on non-infringing formulation





Source: EvaluatePharma, First Word

CHS-1420 Adalimumab Biosimilar: Good Progress



- High-level of analytical similarity achieved
- Process Science and Molecular
- Scale-up according to plan
- CMO pre-agreements for commercial supply

Regulator

Intellectua

Property

- Positive Ph 3 in patients with psoriasis
- ✓ BLA filing expected in H1 '17
- ✓ CHRS wins IPR institution vs. AbbVie '135
- Coherus' awarded 4 formulation patents
- x Adverse '166 IPR Decision
- Scientific and legal strategy in-place to support launch once approved

Source: EvaluatePharma, First Word

Large Revenue Opportunity Humira WW revenues, \$ B **Differentiated IP strategy** may enable market exclusivity for CHS-1420 14.4 12.9 for several years in \$14B+ global Humira opportunity 2014 2015 **IP Hurdles Expected to Limit Competition** Status late-stage biosimilar pipeline⁽¹⁾ Expect to file H1 '17 after study completion and Reg interactions Coherus Approved in 2016 – AMGEN formulation IPRs not instituted Several In different development stages – others unclear IP strategy

(1) With U.S. FDA registration focus



CHS-1420 Adalimumab Biosimilar: Focus on Differentiated IP Strategy to Support early Market Access

1	Dosing IP	 Successfully instituted an IPR against AbbVie's patent '135 Two independent patent office panels agree
2	Formulation IP	 Worked around AbbVie formulation patents '157 and '158; and awarded own patents, posing potential hurdles for other players Advancing additional scientific and legal approaches to address various formulation intellectual property challenges, including AbbVie's '166 patent
3	Additional IP	 We see additional IP as either not relevant or vulnerable to strong invalidity challenges Preliminary injunction by AbbVie considered unlikely



Dosing IP: U.S. Patent Office Instituted '135, '680 and '987 IPRs

The Decision of the US Patent Office (USPTO) on '135 IPR

The USPTO institution decision concluded that "Petitioner [Coherus] establishes a reasonable likelihood that it will prevail in showing that claims 1–5 of the '135 patent are unpatentable."

Selected Excerpts from the USPTO Institution Decision

"[AbbVie's] arguments are premised on a claim construction that we do not adopt..."

"...a skilled artisan would have been led to optimize the dosing regimens disclosed in [van de Putte and Kempeni] " "...we are unpersuaded by [AbbVie's] arguments regarding superiority of the 40 and 80 mg doses to the 20 mg dose "

Note: A different PTAB panel of the USPTO also instituted CHRS IPRs filed in December 2015 against AbbVie's U.S. Patents 9,017,680 and 9,073,987. Both are in the same patent family as the '135 patent claiming insignificant variations of a 40 mg biweekly dosage for RA. Boehringer Ingelheim IPRs against the '135 patent were instituted in June, 2016



Formulation IP: Plan to File Request for Reconsideration of PTAB Decision on IPR of AbbVie U.S. Patent 9,114,166

- On November 7, 2016 the USPTO (PTAB) denied Institution of Coherus' IPR against AbbVie's U.S. Patent 9,114,166
- Coherus believes the PTAB made a number of factual and legal errors
 - Prior art
 - Patentability threshold
 - Prior AbbVie positions
- The company plans to file a request for reconsideration, although such requests may have low historical probability of success

The information contained in this presentation is not intended to communicate any legal opinion on the infringement or validity of any patents



Additional Strategies to Support Path to Market in 2018

- **Technical and Scientific:** Alternative formulations addressing the '166 patent are designed to support a 2018 path to market
- Legal: Continue advancement of defensive and offensive IP strategies to address ongoing formulation IP risks
- **Clinical**: Plan to initiate PK study in H1 2017

Intellectual Property issues and risks will likely remain an industrywide concern, pending further definition of the legal landscape

The information contained in this presentation is not intended to communicate any legal opinion on the infringement or validity of any patents







- Introduction and Company Summary
- Program Highlights
- The Commercial Opportunity



Coherus Applies Rigorous Selection Criteria to Candidate Molecules




Source: EvaluatePharma


Therapeutic Area Franchises Link Coherus Capabilities with Market Needs

		Example: Oncology	Example: Inflammation
Platform Capability	Development of biosimilar candidates	CHS-1701	Anti-TNFs
Strategy	Therapeutic Area Franchises	Oncology Therapeutic Area Franchise	Inflammation Therapeutic Area Franchise
Market Conversion Opportunity	Specific market needs	Episodic, non-chronic care Concentrated sites GPO/provider-driven adoption	Multi-indication, chronic care Large prescriber base Payer-driven adoption

Potential Platform Throughput Enables Therapeutic Franchise Focus to Maximize Market Value



CHS-1701 Pegfilgrastim Biosimilar: **Staged Commercial Launch Preparations Initiated**




CHS-1701 Pegfilgrastim Biosimilar: Expect Good Uptake despite Onpro

Expect good-uptake of pegfilgrastim biosimilar

Filgrastim biosimilar uptake in the U.S.

%, share of Neupogen market in Units



Q3'15

Q3'16

- Share of Neupogen biosimilar currently at ~40% and growing
- Expect even higher uptake of pegfilgrastim biosimilar as it represents higher cost burden to the health system

Neulasta Onpro share expected to be reversible, "non-sticky"

- Neulasta biosimilars expected to win significant share despite Amgen's Onpro kit closing in to 50% market share
- Market research indicates the majority of Onpro switches have been primarily driven by economic incentives and not by patient need
- CHS-1701 commercial strategy expected to provide competitive positioning with respect to all Neulasta formats currently available



Source: IMS

Coherus is Delivering on the Potential of the Platform and Laying the Foundation for Continued Growth

Strong Execution: Delivering on the Platform

- ✓ CHS-1701 BLA accepted
- Positive Phase 3 topline data with CHS-0214
- Positive Phase 3 topline data with CHS-1420
- Differentiated path to market strategy for CHS-1420
- Positive Phase 2b data for novel oral treatment for RRMS (CHS-131)

Strategic Framework: Long Term Value Creation

- Therapeutic Area Franchise approach provides sharp value creation focus
- Commercialization strategy for CHS-1701 in execution
- Licensing efforts for immunology and MS assets underway
- Wave 2 progressing on track



Coherus BioSciences

Jefferies 2016 London Healthcare Conference November 16, 2016



